Company Quick10K Filing
Quick10K
Unum Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$1.90 30 $57
10-Q 2019-09-30 Quarter: 2019-09-30
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
8-K 2019-11-12 Earnings, Exhibits
8-K 2019-11-05 Other Events, Exhibits
8-K 2019-11-04 Other Events, Exhibits
8-K 2019-08-12 Earnings, Exhibits
8-K 2019-07-31 Enter Agreement, Exhibits
8-K 2019-07-26 Officers, Exhibits
8-K 2019-07-19 Officers
8-K 2019-07-02 Other Events, Exhibits
8-K 2019-06-21 Enter Agreement, Exhibits
8-K 2019-06-18 Shareholder Vote
8-K 2019-06-10 Officers, Other Events, Exhibits
8-K 2019-05-13 Earnings, Exhibits
8-K 2019-03-28 Earnings, Exhibits
8-K 2019-03-07 Regulation FD, Exhibits
8-K 2019-01-18 Enter Agreement, Exhibits
8-K 2019-01-04 Regulation FD, Other Events, Exhibits
8-K 2019-01-03 Officers, Other Events, Exhibits
8-K 2018-12-01 Regulation FD
8-K 2018-11-12 Earnings, Exhibits
8-K 2018-08-13 Earnings, Other Events, Exhibits
BMRN Biomarin Pharmaceutical 13,860
XNCR Xencor 2,107
WVE Wave Life Sciences 800
ITCI Intra-Cellular Therapies 460
MRUS Merus 364
REPH Recro Pharma 259
MNKD Mannkind 201
ETTX Entasis Therapeutics Holdings 111
SBOT Stellar Biotechnologies 10
NVUS Novus Therapeutics 9
UMRX 2019-09-30
Part I-Financial Information
Item 1. Financial Statements (Unaudited)
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
Part Ii-Other Information
Item 1. Legal Proceedings.
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Item 6. Exhibits.
EX-10.2 umrx-ex102_13.htm
EX-10.3 umrx-ex103_52.htm
EX-31.1 umrx-ex311_10.htm
EX-31.2 umrx-ex312_7.htm
EX-32.1 umrx-ex321_8.htm
EX-32.2 umrx-ex322_9.htm

Unum Therapeutics Earnings 2019-09-30

UMRX 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 umrx-10q_20190930.htm 10-Q umrx-10q_20190930.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-38443

 

UNUM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

46-5308248

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

 

200 Cambridge Park Drive, Suite 3100

Cambridge, Massachusetts

 

02140

(Address of principal executive offices)

 

(Zip code)

(617) 945-5576

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 Par Value

 

UMRX

 

The Nasdaq Global Select Market

As of November 8, 2019, the registrant had 30,663,054 shares of common stock, $0.001 par value per share, outstanding.

 

 

 

 

 


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plan, objectives of management and expected market growth are forward-looking statements. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. We believe these factors include but are not limited to those described under “Risk Factors” and include, among other things:

 

the success, cost, and timing of our product development activities and clinical trials;

 

our ability to obtain and maintain regulatory approval for our ACTR087 and ACTR707 product candidates and any other product candidates we may develop, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;

 

the potential for our identified research priorities to advance our ACTR and BOXR platform;

 

the ability to license additional intellectual property relating to our product candidates from third-parties and to comply with our existing license agreements and collaboration agreements;

 

the ability and willingness of our third-party research institution collaborators to continue research and development activities relating to our product candidates;

 

our ability to commercialize our products in light of the intellectual property rights of others;

 

our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;

 

the scalability and commercial viability of our manufacturing methods and processes;

 

the commercialization of our product candidates, if approved;

 

our plans to research, develop, and commercialize our product candidates;

 

the potential benefits of our existing collaboration with Seattle Genetics and our ability to attract other collaborators with development, regulatory, and commercialization expertise;

 

future agreements with third parties in connection with the commercialization of our product candidates and any other approved product;

 

the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

 

the rate and degree of market acceptance of our product candidates;

 

the pricing and reimbursement of our product candidates, if approved;

 

regulatory developments in the United States and foreign countries;

 

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

 

the success of competing therapies that are or may become available;

 

our ability to attract and retain key scientific or management personnel;

 

the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;

 

our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;

 

our use of the proceeds from the initial public offering and the concurrent private placement; and

 

our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates.

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Quarterly Report on Form 10-Q. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

i


 

Unum Therapeutics Inc.

Table of Contents

 

 

 

Page

 

PART I—FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

1

 

Consolidated Balance Sheets

1

 

Consolidated Statements of Operations and Comprehensive Loss

2

 

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

3

 

Consolidated Statements of Cash Flows

5

 

Notes to Unaudited Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

29

Item 4.

Controls and Procedures

29

 

PART II—OTHER INFORMATION

 

Item 1.

Legal Proceedings

30

Item 1A.

Risk Factors

30

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

66

Item 6.

Exhibits

67

Signatures

68

 

ii


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

UNUM THERAPEUTICS INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

September 30,

2019

 

 

December 31,

2018

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

45,882

 

 

$

55,671

 

Marketable securities

 

 

 

 

 

22,923

 

Accounts receivable

 

 

880

 

 

 

1,668

 

Prepaid expenses and other current assets

 

 

1,216

 

 

 

740

 

Total current assets

 

 

47,978

 

 

 

81,002

 

Operating lease, right-of-use asset

 

 

5,634

 

 

 

 

Property and equipment, net

 

 

2,170

 

 

 

3,251

 

Restricted cash

 

 

1,255

 

 

 

1,255

 

Other assets

 

 

847

 

 

 

419

 

Total assets

 

$

57,884

 

 

$

85,927

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,594

 

 

$

1,519

 

Accrued expenses and other current liabilities

 

 

6,538

 

 

 

5,477

 

Operating lease liability

 

 

1,581

 

 

 

 

Deferred revenue

 

 

14,717

 

 

 

17,949

 

Total current liabilities

 

 

24,430

 

 

 

24,945

 

Deferred rent

 

 

 

 

 

748

 

Operating lease liability, net of current portion

 

 

4,831

 

 

 

 

Total liabilities

 

 

29,261

 

 

 

25,693

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued

   or outstanding

 

 

 

 

 

 

Common stock, $0.001 par value; 150,000,000 shares authorized; 30,663,054

   shares and 30,057,970 shares issued and outstanding at September 30, 2019 and

   December 31, 2018, respectively

 

 

30

 

 

 

30

 

Additional paid-in capital

 

 

154,782

 

 

 

152,275

 

Accumulated other comprehensive loss

 

 

 

 

 

(12

)

Accumulated deficit

 

 

(126,189

)

 

 

(92,059

)

Total stockholders’ equity

 

 

28,623

 

 

 

60,234

 

Total liabilities and stockholders’ equity

 

$

57,884

 

 

$

85,927

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

1


 

UNUM THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Collaboration revenue

 

$

1,020

 

 

$

2,043

 

 

$

7,211

 

 

$

5,929

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

10,335

 

 

 

10,252

 

 

 

33,355

 

 

 

27,520

 

General and administrative

 

 

2,721

 

 

 

2,367

 

 

 

8,274

 

 

 

5,410

 

Total operating expenses

 

 

13,056

 

 

 

12,619

 

 

 

41,629

 

 

 

32,930

 

Loss from operations

 

 

(12,036

)

 

 

(10,576

)

 

 

(34,418

)

 

 

(27,001

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

31

 

 

 

405

 

 

 

206

 

 

 

745

 

Other income, net

 

 

82

 

 

 

3

 

 

 

82

 

 

 

330

 

Total other income, net

 

 

113

 

 

 

408

 

 

 

288

 

 

 

1,075

 

Net loss

 

 

(11,923

)

 

 

(10,168

)

 

 

(34,130

)

 

 

(25,926

)

Accretion of redeemable convertible preferred stock to redemption value

 

 

 

 

 

 

 

 

 

 

 

(16

)

Net loss attributable to common stockholders

 

$

(11,923

)

 

$

(10,168

)

 

$

(34,130

)

 

$

(25,942

)

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.39

)

 

$

(0.34

)

 

$

(1.12

)

 

$

(1.12

)

Weighted average common shares outstanding, basic and diluted

 

 

30,661,125

 

 

 

29,879,476

 

 

 

30,418,752

 

 

 

23,169,348

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(11,923

)

 

$

(10,168

)

 

$

(34,130

)

 

$

(25,926

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gains (losses) on marketable securities, net of tax of $0

 

 

 

 

 

(11

)

 

 

12

 

 

 

(8

)

Total other comprehensive income (loss)

 

 

 

 

 

(11

)

 

 

12

 

 

 

(8

)

Comprehensive loss

 

$

(11,923

)

 

$

(10,179

)

 

$

(34,118

)

 

$

(25,934

)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2


 

UNUM THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Redeemable Convertible

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2018

 

 

 

 

$

 

 

 

 

30,057,970

 

 

$

30

 

 

$

152,275

 

 

$

(12

)

 

$

(92,059

)

 

$

60,234

 

Issuance of common stock upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

60,852

 

 

 

 

 

 

11

 

 

 

 

 

 

 

 

 

11

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

726

 

 

 

 

 

 

 

 

 

726

 

Unrealized gains on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10

 

 

 

 

 

 

10

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,691

)

 

 

(11,691

)

Balances at March 31, 2019

 

 

 

 

$

 

 

 

 

30,118,822

 

 

$

30

 

 

$

153,012

 

 

$

(2

)

 

$

(103,750

)

 

$

49,290

 

Issuance of common stock upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

541,732

 

 

 

 

 

 

97

 

 

 

 

 

 

 

 

 

97

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

885

 

 

 

 

 

 

 

 

 

885

 

Unrealized gains on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

2

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,516

)

 

 

(10,516

)

Balances at June 30, 2019

 

 

 

 

$

 

 

 

 

30,660,554

 

 

$

30

 

 

$

153,994

 

 

$

 

 

$

(114,266

)

 

$

39,758

 

Issuance of common stock upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

2,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

788

 

 

 

 

 

 

 

 

 

788

 

Unrealized gains on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,923

)

 

 

(11,923

)

Balances at September 30, 2019

 

 

 

 

$

 

 

 

 

30,663,054

 

 

$

30

 

 

$

154,782

 

 

$

 

 

$

(126,189

)

 

$

28,623

 

 

3


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Redeemable Convertible

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Preferred Stock

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Deficit

 

Balances at December 31, 2017

 

 

20,771,850

 

 

$

77,151

 

 

 

 

10,201,690

 

 

$

10

 

 

$

2,499

 

 

$

(16

)

 

$

(51,339

)

 

$

(48,846

)

Adjustment to retained earnings for change

   in accounting policy

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,188

)

 

$

(6,188

)

Issuance of common stock upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

6,368

 

 

 

 

 

 

28

 

 

 

 

 

 

 

 

 

28

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

479

 

 

 

 

 

 

 

 

 

479

 

Unrealized gains on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9

 

 

 

 

 

 

9

 

Accretion of redeemable convertible

   preferred stock to redemption value

 

 

 

 

 

16

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

 

 

 

 

 

 

(16

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,735

)

 

 

(6,735

)

Balances at March 31, 2018

 

 

20,771,850

 

 

$

77,167

 

 

 

 

10,208,058

 

 

$

10

 

 

$

2,990

 

 

$

(7

)

 

$

(64,262

)

 

$

(61,269

)

Conversion of redeemable convertible

   preferred stock to common stock

 

 

(20,771,850

)

 

 

(77,167

)

 

 

 

13,229,362

 

 

 

13

 

 

 

77,154

 

 

 

 

 

 

 

 

$

77,167

 

Issuance of common stock sold in initial

   public offering, net of underwriting

   discounts, commissions and offering costs

 

 

 

 

 

 

 

 

 

5,985,000

 

 

 

6

 

 

 

63,942

 

 

 

 

 

 

 

 

$

63,948

 

Proceeds from private placement concurrent

   with initial public offering

 

 

 

 

 

 

 

 

 

416,666

 

 

 

1

 

 

 

4,999

 

 

 

 

 

 

 

 

$

5,000

 

Issuance of common stock upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

28,162

 

 

 

 

 

 

11

 

 

 

 

 

 

 

 

 

11

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

847

 

 

 

 

 

 

 

 

 

847

 

Unrealized losses on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6

)

 

 

 

 

 

(6

)

Accretion of redeemable convertible

   preferred stock to redemption value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,023

)

 

 

(9,023

)

Balances at June 30, 2018

 

 

 

 

 

 

 

 

 

29,867,248

 

 

$

30

 

 

$

149,943

 

 

$

(13

)

 

$

(73,285

)

 

$

76,675

 

Issuance of common stock upon exercise of

   stock options

 

 

 

 

 

 

 

 

 

57,611

 

 

 

 

 

 

175

 

 

 

 

 

 

 

 

$

175

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

860

 

 

 

 

 

$

 

 

$

860

 

Unrealized losses on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11

)

 

 

 

 

$

(11

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,168

)

 

 

(10,168

)

Balances at September 30, 2018

 

 

 

 

 

 

 

 

 

29,924,859

 

 

$

30

 

 

$

150,978

 

 

$

(24

)

 

$

(83,453

)

 

$

67,531

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4


 

UNUM THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

 

 

 

Nine Months Ended

September 30,

 

 

 

2019

 

 

2018

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(34,130

)

 

$

(25,926

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization expense

 

 

979

 

 

 

969

 

Stock-based compensation expense

 

 

2,399

 

 

 

2,186

 

Realized losses (gains) on sales of marketable securities

 

 

2

 

 

 

 

Net amortization (accretion) of premiums (discounts) on marketable securities

 

 

(55

)

 

 

(159

)

Gain on sale of property and equipment

 

 

(82

)

 

 

 

Non-cash interest expense

 

 

 

 

 

16

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

788

 

 

 

(589

)

Prepaid expenses and other current assets

 

 

(476

)

 

 

(463

)

Operating lease, right-of-use asset

 

 

1,016